Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Women must not be pregnant and must not be breastfeeding.
Have Type II diabetes.
Not taking any medicine for diabetes, or taking one oral medicine for their diabetes.
You may not be if
Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor.
